Dr Reddy's loses patent case with Eli Lilly over Alimta
Updated : June 25, 2018 06:24 AM IST
The court held that the Alimta (pemetrexed for injection) vitamin regimen patent would be infringed by the competitor that had stated its intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022.
In a separate decision on June 15, the District Court also ruled in favor of Lilly in the case of Eli Lilly and Company versus Hospira, Inc.
In October 2017, the Patent Trial and Appeal Board of the US Patent and Trademark Office ruled in the company's favour regarding patentability of the vitamin regimen for Alimta.